Genelux Corporation Common Stock

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead candidate is Olvi-Vec (olvimulogene nanivacirepvec), a modified vaccinia virus strain for ovarian cancer. The company also offers the CHOICE platform and has a licensing agreement with Newsoara BioPharma for Olvi-Vec in China. Incorporated in 2001, it is headquartered in Westlake Village, California.